ArticlemSystems2025
Impact of study design, contamination, and data characteristics on results and interpretation of microbiome studies.
Article in mSystems, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Comparative Evaluation of Enrichment and Selective Culture Strategies for DetectingVector borne and zoonotic diseases (Larchmont, N.Y.) · 2026Article
- Article
- The Programmable Microbiome: Integrative AI and Multi-Omics Frameworks for Precision T2DM Management.Biology · 2026Review
- Urinary Fungal Microbiome and Associations With Overactive Bladder, Antibiotics and Therapy Response.Neurourology and urodynamics · 2026Article
- Decoding the microbial blueprint of pancreatic cancer.Frontiers in medicine · 2026Review
- Microbial community composition and diversity in nodules and rhizosphere soil of bitter white lupine (Frontiers in microbiology · 2026Article
- Microbial dysbiosis in cholangiocarcinoma.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in high-throughput molecular techniques have enabled microbiome studies in low-biomass environments, which pose unique challenges due to contamination risks. While best-practice guidelines can reduce contamination by over 90%, the impact of residual contamination and data set variability on statistical outcomes remains understudied. Here, we quantitatively assessed how study design factors influence microbiome analyses using simulated and real-world data sets. Alpha diversity was affected by sample number and community dissimilarity, but not by the number of unique taxa. Beta diversity was influenced primarily by unique taxa and group dissimilarity, with a marginal effect of sample number. The number of differentially abundant taxa depended on the number of unique taxa but was also influenced by sample number, depending on thealgorithm. Notably, contamination had a marginal impact on weighted beta diversity but altered the number of differentially abundant taxa when at least 10 contaminants were present, with a greater effect as contamination increased. Findings closely mirrored results from seven real-world low-biomass data sets. Overall, group dissimilarity and the number of unique taxa were the primary drivers of statistical outcomes. The DESeq2 algorithm outperformed ANCOM-BC when exposed to stochastically distributed contamination, but algorithms were equivocal under contamination weighted toward one group. In all cases, the rate of false positives in differential abundance analyses was <15%. Importantly, in both simulated and real-world data, contamination rarely impacts whether microbiome differences were detected but did affect the number of differentially abundant taxa. Thus, when validated protocols with internal negative controls are used, residual contamination minimally impacts statistical outcomes. Alpha diversity was affected by sample number and community dissimilarity, but not by the number of unique taxa. Beta diversity was influenced primarily by unique taxa and group dissimilarity, with a marginal effect of sample number. The number of differentially abundant taxa depended on the number of unique taxa but was also influenced by sample number, depending on the algorithm. Notably, contamination had a marginal impact on weighted beta diversity but altered the number of differentially abundant taxa when at least 10 contaminants were present, with a greater effect as contamination increased. Findings closely mirrored results from seven real-world low-biomass data sets. Overall, group dissimilarity and the number of unique taxa were the primary drivers of statistical outcomes. The DESeq2 algorithm outperformed ANCOM-BC when exposed to stochastically distributed contamination, but algorithms were equivocal under contamination weighted toward one group. In all cases, the rate of false positives in differential abundance analyses was <15%. Importantly, in both simulated and real-world data, contamination rarely whether microbiome differences were detected but did affect the number of differentially abundant taxa. Thus, when validated protocols with internal negative controls are used, residual contamination minimally impacts statistical outcomes.IMPORTANCEMicrobiome studies in low-biomass environments face challenges due to contamination. However, even after implementing strict contamination prevention, control, and analysis measures, the impact of residual contamination on the validity of statistical outcomes in such studies remains a topic of ongoing discussion. Our analyses reveal that key drivers of microbiome study outcomes are group dissimilarity and the number of unique taxa, while contamination has minimal impact on statistical outcomes, primarily limited to the number of differentially abundant taxa detected. A common approach to contamination control involves removing taxa based on published contaminant lists. However, our analysis shows that these lists are highly inconsistent across studies, limiting reliability. Instead, our results support the use of internal negative controls as the most robust means of identifying and mitigating contamination. Collectively, data show that low-biomass microbiome studies have reduced power to detect differences between groups. However, when differences are observed, they are unlikely to be contamination-driven. By prioritizing validated protocols that prevent, assess, and eliminate contaminants through the use of internal negative controls, researchers can minimize the impact of contamination and improve the reliability of results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.